The pharmacological CMA activator CA77.1 (an AR7 analog and based on the inhibition of RARα) has been shown to present beneficial effects in AD-related pathology in two different in vivo AD mouse models [20]. The gene discussed is THRA; the disease is Alzheimer disease.